Search articles, concepts, and chapters
4 articles in GJC
Medeiros Felipe A, Walters Thomas R, Kolko Miriam, Coote Michael, Bejanian Marina, Goodkin Margot L et al.
This study found bimatoprost implants effectively lowered IOP like timolol, but the 15μg dose had higher corneal risks. The 10μg implant shows promise for glaucoma adherence, balancing efficacy and safety.
Weinreb Robert N, Liebmann Jeffrey M, Cioffi George A, Goldberg Ivan, Brandt James D, Johnson Chris A et al.
Two large studies found oral memantine (10mg or 20mg daily) did not prevent glaucoma progression over 48 months compared to placebo, indicating it's not an effective neuroprotective treatment.
Lewis Richard A, Christie William C, Day Douglas G, Craven E Randy, Walters Thomas, Bejanian Marina et al.
Bimatoprost SR implants effectively lowered IOP for up to 6 months, comparable to daily drops, with good safety. This offers a promising, sustained treatment option for glaucoma patients.
Day Douglas G, Walters Thomas R, Schwartz Gail F, Mundorf Thomas K, Liu Charlie, Schiffman Rhett M et al.
This study found preservative-free bimatoprost 0.03% is equally effective and safe as standard bimatoprost 0.03% for lowering intraocular pressure in glaucoma/ocular hypertension, offering a new treatment option.
All 4 articles loaded